UPM Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

UPM Pharmaceuticals is an established, independent CDMO with a strong legacy in late-stage and commercial-scale pharmaceutical manufacturing. Operating from a large, integrated facility in Bristol, Tennessee, the company provides comprehensive services from formulation development through packaging, with significant annual production capacity. Its key differentiators include its family-owned structure, which promises flexibility and transparency, and its specialized capabilities in handling complex and potent drug substances for a diverse client base.

Drug DeliverySmall Molecules

Technology Platform

Integrated CDMO services for oral solid and semi-solid dosage forms, with specialized expertise in high-potent compound handling, hormones, and DEA-controlled substances. Capabilities span formulation development, analytical testing, cGMP manufacturing, scale-up, packaging, and warehousing.

Opportunities

The growing trend of pharmaceutical outsourcing, especially among virtual and small biotechs, provides a expanding client base.

UPM's niche in handling potent and controlled substances represents a high-barrier, high-margin segment with less competition.

Its integrated, end-to-end service model and family-owned flexibility are strong differentiators in attracting partners seeking a transparent, long-term manufacturing relationship.

Risk Factors

The company faces significant regulatory compliance risks from the FDA and DEA, especially given its work with controlled substances.

Operational risks include execution failures in complex manufacturing processes and potential client concentration.

The CDMO market is highly competitive, which could pressure pricing and margins over time.

Competitive Landscape

UPM competes in the crowded small molecule CDMO space against large public players (e.g., Catalent, Lonza, Recipharm) and numerous smaller, niche providers. Its primary competitive differentiation is its combination of large-scale, enterprise-level capabilities with the personalized service of a family-owned business, along with its specialized expertise in potent and controlled substances, which is a narrower, high-barrier niche.

More companies in Small Molecule Drugs →More companies in United States →